AzTrials
AzTrials

Takotsubo SyndromeGEISTNCT04361994

The GErman Italian Spanish Takotsubo (GEIST) Registry

An observational study of Takotsubo Syndrome, run by Prof. Dr. med. Ingo Eitel at 2 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography /echocardiography / coronary angiography parameters, treatment and medication), in-hospital… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Takotsubo Syndrome
How many people
500 participants
Where
2 sitesin 2 countries
Study dates
Apr 2015to Dec 2035
How long will I take part?
6 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Diagnosed according to the current diagnostic recommendations at the time of clinical presentation

Who may be able to join

  • Patients with Takotsubo syndrome

Who cannot join

  • Non

Trial locations and contacts

2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Ingo Eitel, Prof. Dr. contact

004945150044501

ingo.eitel@uksh.de

Thomas Stiermaier, Dr. contact

2 sites in 2 countries

Germany1 site, 1 recruiting

  • Universität zu Lübeck

    Lübeck, Schleswig-Holstein, 23538

    Ingo Eitel, Prof. Dr. med.

    Thomas Stiermaier, Dr.med

    Recruiting

Other trials in Germany

Italy1 site, 1 recruiting

  • University of Foggia

    Foggia

    Franceso Santoro, Dr.

    Daniele Brunetti, Prof. Dr.

    Recruiting

Other trials in Italy

About this study

GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography /echocardiography / coronary angiography parameters, treatment and medication), in-hospital course and complications and short-/long-term outcome are collected prospectively and retrospectively to increase the understanding of the disease.

Read the detailed description

The open-ended, multicenter, international GEIST registry collects data from patients with Takotsubo syndrome during the index hospitalization and follow-up. Furthermore, long-term outcome data are acquired with structured telephone interviews, in case patients do not undergo regular outpatient visits in the participating study centers. The GEIST registry retrospectively includes data, which have already been collected, and prospectively continues to enroll patients with newly diagnosed Takotsubo syndrome.

Medical subject headings
Takotsubo Cardiomyopathy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All-cause mortality

    All-cause mortality (in-hospital, short-term, long-term)

    Measured: Day 0

  2. All-cause mortality

    All-cause mortality (in-hospital, short-term, long-term)

    Measured: 3 Month

  3. All-cause mortality

    All-cause mortality (in-hospital, short-term, long-term)

    Measured: 6 Month

Secondary outcomes (1)

  1. In-Hospital complications

    Cardiogenic shock, pulmonary edema, death, life-threatening arrhythmias, ventricular thrombus formation, right ventricular involvement

    Measured: Day 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2020
  2. Study startApr 2015
  3. Primary completionDec 2035 (estimated)
  4. Study completionDec 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04361994
Sponsor's protocol ID
00
Acronym
GEIST
Status last verified
Dec 2025
First submitted
22 Apr 2020
Last updated
26 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Raposeiras-Roubin S, Santoro F, Arcari L, Vazirani R, Novo G, Uribarri A, Enrica M, Lopez-Pais J, Guerra F, Alfonso F, Patz T, Fernandez-Cordon C, Montisci R, Corbi-Pascual M, Marchetti MF, Almendro M, Cacciotti L, Vedia O, El-Battrawy I, Blanco-Ponce E, Brunetti ND, Akin I, Martinez-Selles M, Thiele H, Stiermaier T, Eitel I, Nunez-Gil IJ; GEIST Researchers. Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry. JACC Heart Fail. 2025 May;13(5):815-825. doi: 10.1016/j.jchf.2024.11.015. Epub 2025 Feb 5.

    PubMed 39918532

  • Santoro F, Stiermaier T, Nunez Gil IJ, El-Battrawy I, Patz T, Cacciotti L, Guerra F, Novo G, Musumeci B, Volpe M, Mariano E, Caldarola P, Montisci R, Ragnatela I, Cetera R, Vazirani R, Lluch C, Uribarri A, Corbi-Pascual M, Conty Cardona DA, Akin I, Barbato E, Thiele H, Brunetti ND, Eitel I, Arcari L. Renin angiotensin system inhibitors and outcome in patients with takotsubo syndrome: A propensity score analysis of the GEIST registry. Am Heart J. 2024 Dec;278:127-138. doi: 10.1016/j.ahj.2024.08.019. Epub 2024 Sep 10.

    PubMed 39260785

  • El-Battrawy I, Santoro F, Nunez-Gil IJ, Patz T, Arcari L, Abumayyaleh M, Guerra F, Novo G, Musumeci B, Cacciotti L, Mariano E, Caldarola P, Parisi G, Montisci R, Vitale E, Volpe M, Corbi-Pasqual M, Martinez-Selles M, Almendro-Delia M, Sionis A, Uribarri A, Thiele H, Brunetti ND, Eitel I, Akin I, Stiermaier T. Age-Related Differences in Takotsubo Syndrome: Results From the Multicenter GEIST Registry. J Am Heart Assoc. 2024 Feb 20;13(4):e030623. doi: 10.1161/JAHA.123.030623. Epub 2024 Feb 13.

    PubMed 38348805

  • Stiermaier T, Walliser A, El-Battrawy I, Patz T, Mezger M, Rawish E, Andres M, Almendro-Delia M, Martinez-Selles M, Uribarri A, Perez-Castellanos A, Guerra F, Novo G, Mariano E, Musumeci MB, Arcari L, Cacciotti L, Montisci R, Akin I, Thiele H, Brunetti ND, Nunez-Gil IJ, Santoro F, Eitel I. Happy Heart Syndrome: Frequency, Characteristics, and Outcome of Takotsubo Syndrome Triggered by Positive Life Events. JACC Heart Fail. 2022 Jul;10(7):459-466. doi: 10.1016/j.jchf.2022.02.015. Epub 2022 May 4.

    PubMed 35772855

  • El-Battrawy I, Santoro F, Stiermaier T, Moller C, Guastafierro F, Novo G, Novo S, Mariano E, Romeo F, Romeo F, Thiele H, Guerra F, Capucci A, Giannini I, Brunetti ND, Eitel I, Akin I. Incidence and Clinical Impact of Right Ventricular Involvement (Biventricular Ballooning) in Takotsubo Syndrome: Results From the GEIST Registry. Chest. 2021 Oct;160(4):1433-1441. doi: 10.1016/j.chest.2021.04.072. Epub 2021 May 27.

    PubMed 34052189

Questions about this trial

What is this clinical trial studying?

An observational study of Takotsubo Syndrome, run by Prof. Dr. med. Ingo Eitel at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany, Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ingo Eitel, Prof. Dr. (004945150044501, ingo.eitel@uksh.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All-cause mortality (time frame: Day 0). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04361994, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Dec 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in